Onkopipeline

, Volume 2, Issue 2, pp 53–58 | Cite as

Leukemias

Overview
GRAND ROUNDS ÜBERBLICK
  • 42 Downloads

Abstract

Leukemias are a heterogeneous group of blood diseases in all age groups. Leukemias have traditionally served as models for tumor diseases. The term was coined in 1847 to report patients with what was later recognized to be chronic myeloid leukemia (CML). The elucidation of CML pathogenesis led to a rationally designed therapy targeted at the cause of the disease. Life expectancy of CML has increased to a median of > 25 years.

Advances have been made with molecular characterization and therapy also in the other leukemias. Progress is facilitated by new modes of cooperation, such as the European LeukemiaNet which comprises leukemia study groups and their interdisciplinary partner groups in 33 countries caring for some 10,000 leukemia patients across Europe.

Key Words:

Leukemia CML European LeukemiaNet 

Leukämien. Übersicht

Zusammenfassung

Leukämien sind eine heterogene Gruppe von Blutkrankheiten in allen Altersgruppen. Leukämien dienen traditionell als Modell für Tumorerkrankungen. Der Begriff „Leukämie“ wurde 1847 für Patienten mit, wie später erkannt wurde, chronischer myeloischer Leukämie (CML) geprägt. Die Aufklärung der CML-Pathogenese führte zu einer rational entwickelten, molekular gezielten Therapie gegen die Krankheitsursache. Die Lebenserwartung bei CML hat sich dadurch im Median auf > 25 Jahre verlängert.

Neue Erkenntnisse wurden auch bei der molekularen Charakterisierung und Therapie der anderen Leukämien gewonnen. Weitere Fortschritte werden durch moderne Kooperationsmodelle wie das European LeukemiaNet, das Leukämiestudiengruppen und ihre interdisziplinären Partnergruppen in 33 Ländern zusammenführt, erleichtert. Die Gruppen behandeln europaweit mehrere 10 000 Leukämiepatienten.

Schlüsselwörter:

Leukämien CML Leukämienetz 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809–20.PubMedCrossRefGoogle Scholar
  2. 2.
    Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:4173–9.PubMedGoogle Scholar
  3. 3.
    Daley GQ, van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824–30.PubMedCrossRefGoogle Scholar
  4. 4.
    Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038–42.PubMedCrossRefGoogle Scholar
  5. 5.
    Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Fabarius A, Li R, Yerganian G, et al. Specific clones of spontaneously evolving karyotypes generate individuality of cancers. Cancer Genet Cytogenet 2008;180:89–99.PubMedCrossRefGoogle Scholar
  7. 7.
    Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–56.PubMedCrossRefGoogle Scholar
  8. 8.
    Hehlmann R, Berger U, Aul C, et al. The German Competence Network “Acute and Chronic Leukemias”. Leukemia 2004;18:665–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet 2007;370:342–50.PubMedCrossRefGoogle Scholar
  10. 10.
    Heisterkamp N, Jenster G, ten Hoeve J, et al. Acute leukaemia in bcr/abl transgenic mice. Nature 1990;344:251–3.PubMedCrossRefGoogle Scholar
  11. 11.
    James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Kralovics R, Teo SS, Buser AS, et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 2005;106:3374–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Lengfelder E, Schultheis B, Büchner T, Hehlmann R. Arsentrioxid: “ein erfolgreiches Gift” bei Patienten mit akuter Promyelozytenleukämie. Dtsch Med Wochenschr 2007;132:330–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Müller MC, Erben P, Saglio G, et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 2008;22:96–102.PubMedCrossRefGoogle Scholar
  15. 15.
    Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Sanz MA, Grimwade D, Tallman MS, et al. Guidelines on the management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113:1875–91.PubMedCrossRefGoogle Scholar
  17. 17.
    Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909–18.PubMedCrossRefGoogle Scholar
  18. 18.
    Shtivelman E, Lifshitz B, Gale RP, et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985;315:550–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Tam CS, O’Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975–80.PubMedCrossRefGoogle Scholar
  20. 20.
    Virchow R. Weiβes Blut (Leukämie). Arch Pathol Anat 1847;1:563.CrossRefGoogle Scholar

Copyright information

© Springer 2009

Authors and Affiliations

  1. 1.III. Medizinische Universitätsklinik MannheimMedizinische Fakultät Mannheim der Universität HeidelbergMannheimGermany
  2. 2.III. Medizinische Universitätsklinik MannheimMedizinische Fakultät Mannheim der Universität HeidelbergMannheimGermany

Personalised recommendations